Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Further Analysis of the Phase 2b ADVANCE Study Reinforces Phase 2b EXPAND Results ...

7 September 2026 · By · Wire by Fusion42

Published

7 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at accessnewswire.com →

◆ Verified

Fusion42 · 7 September 2026 · Fusion42 review

SynAct Pharma's post-hoc analysis of its Phase 2b ADVANCE study confirms results from the earlier EXPAND study showing resomelagon's clinical benefit in rheumatoid arthritis patients and supports planned Phase 3 trials, with FDA discussions scheduled for Q4 2026.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

The FDA's upcoming input on the Phase 3 trial design creates a narrow window to shape resomelagon's development path and potential approval. You should prepare to adapt your RA drug trials to tighter clinical standards and anticipate competitive shifts when the Phase 3 data arrives.

◆ Coverage

2 sources · 7 Sep 2026

◆ Related on Wire

◆ Topics

Biotechrheumatoid-arthritisphase-2bphase-3fda-meetingresomelagonclinical-trial